Core Viewpoint - Wanfu Bio is expected to report its worst performance since its IPO in 2015, with a projected net profit of 46 million to 69 million yuan for 2025, representing a year-on-year decline of 87.71% to 91.81% [1] Group 1: Financial Performance - The company anticipates a non-net profit of -7.5 million to -15 million yuan for 2025, marking its first-ever loss in this category since going public [2] - The decline in main business revenue is attributed to a drop in domestic income, influenced by VAT rate adjustments and policy impacts on hospital business, leading to pressure on both volume and price [2] - Factors contributing to the decline in net profit include price reductions in the domestic market, changes in product structure, a decrease in consolidated gross margin, high R&D and sales expenses, and impairment losses from divesting non-core, low-profitability businesses [2] Group 2: Market Performance - Despite domestic market challenges, Wanfu Bio has seen stable growth in overseas markets, particularly in North America, where a long-term supply agreement for respiratory products has been established [3] - The company's stock price has underperformed, with a cumulative decline of 9.15% in 2025, compared to a 29.87% increase in the overall market, and a drop of over 70% from its peak in 2020 [3][4] Group 3: Strategic Initiatives - To reverse the declining performance and stock price, the company is focusing on product specialization, cost control, channel upgrades, accelerated overseas expansion, governance optimization, and market value management [4] - The company has decided to postpone the implementation of the "Knowledge City Production Base Construction Project" to avoid resource waste and improve the efficiency of fundraising, given the significant changes in the internal and external operating environment [4] Group 4: Future Outlook - For 2026, the company plans to leverage market recovery in the domestic sector, focusing on core product lines to improve revenue, while continuing to expand in overseas markets [5] - The company aims to commercialize AI applications in pathology and clinical diagnostics, and to enhance its business from point-of-care (POC) to in vitro diagnostics (IVD), accelerating its international expansion [5]

在上市第十年之际，万孚生物（300482）将交出一份上市以来业绩最差的成绩单。 万孚生物2025年业绩预告显示，公司2025年预计归属净利润为4600万元至6900万元，同比预降87.71%至91.81%。这也 将是万孚生物自2015年上市以来的最差业绩。 针对2025年业绩变动的原因，万孚生物表示，公司主营业务收入同比下滑，主要原因是国内收入下滑，一方面受增值 税税率调整影响，另一方面院内业务受到医疗行业政策影响，量价承压。 此外，万孚生物表示，归属净利润同比下滑，有以下几方面原因，一是由于国内市场终端降价、产品结构变化，合并 报表毛利率下降；二是公司为了夯实产品竞争力，开拓新市场、新应用场景，仍然维持了较高的研发支出和销售费 用；三是对于非核心的、盈利能力较弱的业务进行剥离，产生了一定的减值损失。 值得一提的是，2025年万孚生物在海外市场取得了不错的成绩。万孚生物表示，国内市场，基层医疗市场胶体金和荧 光产品线收入下滑，盈利减少。而海外市场业务稳健发展，为公司整体的可持续增长提供了重要支撑点。其中，在北 美市场，呼吸道业务的导入带来明显增量，与美国大客户基于呼吸道三联检产品签署长期供货协议，为美国呼吸道 ...

2025年年底，公司进入新品收获期，多个重要单品获证。顺利取得胶体金平台呼吸道合胞病毒/肺炎支原体/腺病毒三联检 试剂盒的注册证；分子平台的WonNova 1600全自动核酸提纯及实时荧光PCR分析系统及配套呼吸道六联检试剂（覆盖甲型流感 病毒、乙型流感病毒、呼吸道合胞病毒、腺病毒、副流感病毒及肺炎支原体）获证，适配口咽拭子样本，满足临床高发呼吸道 感染的快速通量筛查需求；化学发光平台的MiniTLA LA-6400全自动生化免疫流水线正式上市，精准适配中小型实验室及急诊 场景需求，强化了公司在门急诊领域深耕的能力。 在投资和生态建设层面，公司直投的数字化和AI病理项目，在国家医疗卫生新政的引领下，迎来了业务的快速增长。公司 研发申报的"出凝血疾病智能辅助分析软件"成功入选由工业和信息化部主办的"2025年人工智能医疗器械创新任务揭榜挂帅单 位名单"，标志着公司在AI辅助诊疗领域的战略布局取得实质性突破，为后续满足临床需求及商业化应用奠定坚实基础。 2026年，国内市场，借助复苏，抓稳基层。以发光和分子产品线，实现医院中心实验室的持续渗透，收入迅速改善。海外 和北美市场，继续发挥品牌和渠道优势，扩大覆盖实现高 ...

在海外市场，万孚生物业务持续增长，海外收入占比首次超过国内业务，为公司可持续增长提供了重要 支撑。公司深化重点国家本地化进程，在国际市场的中小实验室份额占比持续提升。在北美市场，呼吸 道业务的导入带来明显增量，与美国大客户签署呼吸道三联检产品长期供货协议，为美国呼吸道传染病 业务的战略布局打下坚实基础。 2025年底，万孚生物进入新品收获期，多个重要单品获得注册证。在投资和生态建设层面，公司直投的 数字化和AI病理项目在国家医疗卫生新政的引领下，迎来了业务的快速增长。公司研发申报的"出凝血 疾病智能辅助分析软件"成功入选由工信部"2025年人工智能医疗器械创新任务揭榜挂帅单位名单"，标 志着公司在AI辅助诊疗领域的战略布局取得实质性突破，为后续满足临床需求及商业化应用奠定坚实 基础。 万孚生物表示，2026年公司将以发光和分子产品线推动医院中心实验室的持续渗透和收入迅速改善。在 海外市场，公司将继续发挥品牌和渠道优势，扩大覆盖实现增长。在创新层面，公司将借助利好政策， 通过已有AI布局和突破，在病理和临床诊断方面实现商业化落地。 中证报中证网讯(记者武卫红)1月9日晚，万孚生物（300482）发布2025年度 ...

证券日报网讯 1月9日，万孚生物发布公告称，公司预计2025年归属于上市公司股东的净利润为4600万 元～6900万元，比上年同期56162.85万元下降91.81%～87.71%。 （文章来源：证券日报） ...

万孚生物表示，公司归属净利润同比下滑，有以下几方面原因，一是由于国内市场终端降价、产品结构 变化，合并报表毛利率下降；二是公司为了夯实产品竞争力，开拓新市场、新应用场景，仍然维持了较 高的研发支出和销售费用；三是对于非核心的、盈利能力较弱的业务进行剥离，产生了一定的减值损 失。 北京商报讯（记者 丁宁）1月9日晚间，万孚生物（300482）发布2025年业绩预告显示，公司2025年预 计归属净利润为4600万元至6900万元，同比预降87.71%至91.81%。 ...

Group 1 - Gree Co., Ltd. plans to use no more than 6 billion yuan of idle self-owned funds for entrusted wealth management, with a validity period of one year from the date of board approval [1] - Guosheng Technology's stock will resume trading on January 12 after completing an investigation into abnormal trading, but the company expects a net loss for 2025 [2] - Dongzhu Ecology is negotiating to terminate the acquisition of control over Kairui Xingtong due to failure to reach an agreement on valuation and other commercial terms [3] Group 2 - Jiaoyun Co., Ltd. intends to swap its passenger car sales and automotive after-service assets with the cultural and tourism-related assets of its controlling shareholder, which is expected to constitute a major asset restructuring [4] - Baogang Co., Ltd. plans to adjust the related transaction price of rare earth concentrate for the first quarter of 2026 to 26,834 yuan per ton, a slight increase from the previous quarter [5] - Luzhou Laojiao proposes a cash dividend of 13.58 yuan per 10 shares, totaling approximately 2 billion yuan [6] Group 3 - Zhenlei Technology states that the commercial aerospace industry is still in its early industrialization stage, with unpredictable contributions to revenue from batch launches [7][8] - China First Heavy Industries has only undertaken a small number of projects related to "controlled nuclear fusion," and these products have not yet generated revenue [9] - Huanxu Electronics plans to invest 30 million yuan in a private equity fund focused on AI-driven new generation information technology industries [10] Group 4 - Ruina Intelligent plans to invest approximately 169.9 million yuan to build a modern intelligent high-efficiency heat pump R&D and production base [11] - Hualan Biological intends to acquire a 35% stake in Ningbo Guangfeng Capsule Co., Ltd. for 8.4647 million yuan, with plans for further acquisitions in the future [12] - Yili Media reports that its main business and business model have not undergone significant changes, and its operations are normal [13] Group 5 - Jushi Chemical received a notice of administrative penalty for inflating revenue and profits through false trading, with a proposed fine of 2.4 million yuan [14] - Haiyou New Materials has been designated as a supplier for a well-known automotive glass manufacturer to develop and supply PDLC dimming film products [15][16] - Shanda Electric signed a strategic cooperation agreement with Shandong Development New Energy Co., Ltd. to promote the technological upgrade and large-scale development of the new energy industry in Shandong Province [17] Group 6 - China Shipbuilding Defense expects a net profit increase of 149.61% to 196.88% for 2025, driven by improved ship product revenue and production efficiency [18] - Daotong Technology anticipates a net profit increase of 40.42% to 45.1% for 2025, fueled by AI-driven services [19] - Zhenhua New Materials expects a net loss of 400 million to 500 million yuan for 2025 due to declining market demand for existing products [20] Group 7 - Greenland Holdings anticipates a net loss of 16 billion to 19 billion yuan for 2025, primarily due to declining asset prices and increased financial expenses [21] - Electric Wind Power expects a net loss of 890 million to 1.09 billion yuan for 2025, attributed to intensified competition and delays in project construction [22] - Jintou City Development forecasts a net loss for 2025 [23] Group 8 - Dazhi expects a net loss for 2025 [25] - Wantong Development anticipates a net loss for 2025 [26] - Wanfu Biological projects a net profit decline of 87.71% to 91.81% for 2025 due to market price reductions and increased R&D expenses [27] Group 9 - Zhongkong Technology expects a net profit decline of 53.07% to 61.85% for 2025, driven by economic slowdown and reduced customer demand [28] - Jian Kai Technology's shareholder plans to reduce holdings by up to 3% [29] - Huati Technology's actual controller plans to reduce holdings by up to 3% [30]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

公司主营业务收入同比下滑，主要原因是国内收入下滑，一方面增值税税率调整影响，另一方面院内业 务受到医疗行业政策影响，量价承压；海外业务发展稳健，为公司整体的可持续增长提供了重要支撑 点。公司归母净利润同比下滑，有以下几方面原因：1）由于国内市场终端降价、产品结构变化，合并 报表毛利率下降；2）公司为了夯实产品竞争力，开拓新市场、新应用场景，仍然维持了较高的研发支 出和销售费用；3）对于非核心的、盈利能力较弱的业务进行剥离，产生了一定的减值损失。 格隆汇1月9日丨万孚生物(300482.SZ)公布，预计2025年归属于上市公司股东的净利润4,600万元～6,900 万元，比上年同期下降91.81%～87.71%，扣除非经常性损益后的净利润-1,500万元～-750万元。 ...

公告称，公司主营业务收入同比下滑，主要原因是国内收入下滑。 智通财经APP讯，万孚生物(300482.SZ)披露2025 年度业绩预告，公司预计归属于上市公司股东的净利 润4600万元至6900万元，同比下降87.71%至91.81%;扣除非经常性损益后的净亏损750万元至1500万元。 ...